Free Trial

Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics logo with Medical background

Cantor Fitzgerald began coverage on shares of Keros Therapeutics (NASDAQ:KROS - Free Report) in a report released on Thursday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating on the stock.

Several other research analysts also recently commented on the stock. Scotiabank started coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 price objective for the company. Bank of America lowered their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Finally, Guggenheim initiated coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a "buy" rating and a $96.00 price objective on the stock. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics has a consensus rating of "Buy" and an average target price of $89.11.

Check Out Our Latest Analysis on Keros Therapeutics

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded up $1.57 during mid-day trading on Thursday, reaching $59.56. The company had a trading volume of 366,465 shares, compared to its average volume of 369,702. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -11.55 and a beta of 1.23. The business's 50-day simple moving average is $54.33 and its 200 day simple moving average is $51.94. Keros Therapeutics has a one year low of $27.02 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter in the prior year, the company posted ($1.27) earnings per share. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.88 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the business's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares in the company, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 22.90% of the company's stock.

Institutional Trading of Keros Therapeutics

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its position in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics during the third quarter worth about $89,000. Assenagon Asset Management S.A. raised its position in shares of Keros Therapeutics by 814.6% during the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company's stock worth $12,990,000 after acquiring an additional 199,245 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Keros Therapeutics by 21.3% in the third quarter. Handelsbanken Fonder AB now owns 9,700 shares of the company's stock worth $563,000 after acquiring an additional 1,700 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics in the second quarter valued at approximately $128,000. Institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Recommended Stories

Analyst Recommendations for Keros Therapeutics (NASDAQ:KROS)

Should you invest $1,000 in Keros Therapeutics right now?

Before you consider Keros Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.

While Keros Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines